ADAR1 Regulates the ERK/c-FOS/MMP-9 Pathway to Drive the Proliferation and
Migration of Non-small Cell Lung Cancer Cells.
10.3779/j.issn.1009-3419.2025.106.26
- Author:
Li ZHANG
1
;
Xue PAN
1
;
Wenqing YAN
1
;
Shuilian ZHANG
1
;
Chiyu MA
1
;
Chenpeng LI
1
;
Kexin ZHU
1
;
Nijia LI
1
;
Zizhong YOU
1
;
Xueying ZHONG
1
;
Zhi XIE
1
;
Zhiyi LV
1
;
Weibang GUO
1
;
Yu CHEN
1
;
Danxia LU
1
;
Xuchao ZHANG
1
Author Information
1. Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou 510080, China.
- Publication Type:Journal Article
- Keywords:
ADAR1;
Lung neoplasms;
MMP-9;
Non-small cell lung cancer;
Tumor metastasis
- MeSH:
Humans;
Lung Neoplasms/physiopathology*;
Adenosine Deaminase/genetics*;
Matrix Metalloproteinase 9/genetics*;
Cell Proliferation;
Carcinoma, Non-Small-Cell Lung/physiopathology*;
Cell Movement;
Animals;
Mice;
RNA-Binding Proteins/genetics*;
Female;
Male;
Cell Line, Tumor;
Proto-Oncogene Proteins c-fos/genetics*;
Middle Aged;
MAP Kinase Signaling System;
Gene Expression Regulation, Neoplastic;
Mice, Nude;
Extracellular Signal-Regulated MAP Kinases/genetics*
- From:
Chinese Journal of Lung Cancer
2025;28(9):647-657
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Double-stranded RNA-specific adenosine deaminase 1 (ADAR1) binds to double-stranded RNA and catalyzes the deamination of adenosine (A) to inosine (I). The functional mechanism of ADAR1 in non-small cell lung cancer (NSCLC) remains incompletely understood. This study aimed to investigate the prognostic significance of ADAR1 in NSCLC and to elucidate its potential role in regulating tumor cell proliferation and migration.
METHODS:Data from The Cancer Genome Atlas (TCGA) and cBioPortal were analyzed to assess the correlation between high ADAR1 expression and clinicopathological features as well as prognosis in lung cancer. We performed Western blot (WB), cell proliferation assays, Transwell invasion/migration assays, and nude mouse xenograft modeling to examine the phenotypic changes and molecular mechanisms induced by ADAR1 knockdown. Furthermore, the ADAR1 p150 overexpression model was utilized to validate the proposed mechanism.
RESULTS:ADAR1 expression was significantly elevated in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) tissues compared with adjacent non-tumor tissues (LUAD: P=3.70×10-15, LUSC: P=0.016). High ADAR1 expression was associated with poor prognosis (LUAD: P=2.03×10-2, LUSC: P=2.81×10-2) and distant metastasis (P=0.003). Gene Set Enrichment Analysis (GSEA) indicated that elevated ADAR1 was associated with mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway activation, matrix metalloproteinase-9 (MMP-9) expression, and cell adhesion. ADAR1 and MMP-9 levels showed a strongly positive correlation (P=6.45×10-34) in 10 lung cancer cell lines, highest in H1581. Knockdown of ADAR1 in H1581 cells induced a rounded cellular morphology with reduced pseudopodia. Concomitantly, it suppressed cell proliferation, invasion, migration, and in vivo tumorigenesis. It also suppressed ERK phosphorylation and downregulated cellular Finkel-Biskis-Jinkins murine osteosarcoma viral oncogene homolog (c-FOS), MMP-9, N-cadherin, and Vimentin. Conversely, ADAR1 p150 overexpression in PC9 cells enhanced ERK phosphorylation and increased c-FOS and MMP-9 expression.
CONCLUSIONS:High ADAR1 expression is closely associated with poor prognosis and distant metastasis in NSCLC patients. Mechanistically, ADAR1 may promote proliferation, invasion, migration, and tumorigenesis in lung cancer cells via the ERK/c-FOS/MMP-9 axis.
